Table 1.
Sociodemographic characteristics of people with lung, prostate, breast and colorectal cancer from 2006–2018, for those with and without specialist mental health or addiction (SMHA) service use in the five years before cancer diagnosis
| Characteristics | People not using SMHA services | People using SMHA services | People not using SMHA services | People using SMHA services | People not using SMHA services | People using SMHA services | People not using SMHA services | People using SMHA services |
|---|---|---|---|---|---|---|---|---|
| Lung cancer | Prostate cancer | Breast cancer | Colorectal cancer | |||||
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Total | 22,958 (100.0) | 1,125 (100.0) | 37,323 (100.0) | 794 (100.0) | 34,404 (100.0) | 1,442 (100.0) | 33,615 (100.0) | 1,027 (100.0) |
| Gender | ||||||||
| Female | 11,006 (47.9) | 553 (49.2) | 0 | 0 | 34,404 (100.0) | 1,442 (100.0) | 15,977 (47.5) |
530 (51.6) |
| Male | 11,952 (52.1) | 572 (50.8) | 37,323 (100.0) | 794 (100.0) | 0 | 0 | 17,638 (52.5) |
497 (48.4) |
| Age (years) | ||||||||
| 15–44 |
314 (1.4) |
43 (3.8) |
92 (0.2) |
4 (0.5) |
3,756 (10.9) | 229 (15.9) |
1,311 (3.9) |
108 (10.5) |
| 45–54 |
1,563 (6.8) |
203 (18.0) |
2,056 (5.5) |
82 (10.3) |
8,830 (25.7) | 463 (32.1) |
2,477 (7.4) |
130 (12.7) |
| 55–64 | 4,564 (19.9) | 333 (29.6) | 10,473 (28.1) |
279 (35.1) |
8,650 (25.1) | 375 (26.0) | 5,584 (16.6) |
216 (21.0) |
| 65–74 | 7,582 (33.0) | 322 (28.6) | 15,728 (42.1) |
272 (34.3) |
6,892 (20.0) | 180 (12.5) | 9,800 (29.2) |
231 (22.5) |
| 75+ | 8,935 (38.9) | 224 (19.9) | 8,974 (24.0) |
157 (19.8) |
6,276 (18.2) | 195 (13.5) | 14,443 (43.0) |
342 (33.3) |
| Ethnicity | ||||||||
| Māori | 4,056 (17.7) | 293 (26.0) |
2,310 (6.2) |
87 (11.0) |
4,124 (12.0) | 284 (19.7) |
1,731 (5.1) |
112 (10.9) |
| Non-Māori | 18,902 (82.3) | 832 (74.0) | 35,013 (93.8) |
707 (89.0) |
30,280 (88.0) | 1,158 (80.3) | 31,884 (94.9) |
915 (89.1) |
| Deprivation quintile | ||||||||
| 1 (low) | 2,803 (12.3) |
91 (8.1) |
7,794 (20.9) |
115 (14.5) |
6,791 (19.8) | 175 (12.2) | 6,013 (17.9) |
145 (14.1) |
| 2 | 3,347 (14.6) | 122 (10.9) | 7,337 (19.7) |
122 (15.4) |
6,550 (19.1) | 221 (15.4) | 6,215 (18.5) |
142 (13.8) |
| 3 | 4,432 (19.4) | 202 (18.0) | 7,827 (21.0) |
138 (17.4) |
6,902 (20.1) | 310 (21.6) | 7,224 (21.6) |
211 (20.5) |
| 4 | 5,690 (24.9) | 333 (29.6) | 8,129 (21.8) |
213 (26.8) |
7,308 (21.3) | 368 (25.6) | 7,919 (23.6) |
273 (26.6) |
| 5 (high) | 6,601 (28.9) | 376 (33.5) | 6,177 (16.6) |
206 (25.9) |
6,776 (19.7) | 364 (25.3) | 6,137 (18.3) |
256 (24.9) |
| Stage at diagnosis | ||||||||
| Localised |
1,424 (6.2) |
63 (5.6) |
84 (10.6) |
5,297 (14.2) | 18,069 (52.5) | 722 (50.1) | 7,615 (22.7) |
214 (20.8) |
| Regionally spread | 2,954 (12.9) | 170 (15.1) |
55 (6.9) |
3,300 (8.8) |
11,336 (32.9) | 470 (32.6) | 12,769 (38.0) |
343 (33.4) |
| Distant metastases | 10,629 (46.3) | 493 (43.8) |
82 (10.3) |
2,158 (5.8) |
1,244 (3.6) |
49 (3.4) |
6,721 (20.0) |
258 (25.1) |
| Unknown | 7,951 (34.6) | 399 (35.5) |
573 (72.2) |
26,568 (71.2) | 3,755 (10.9) | 201 (13.9) | 6,510 (19.4) |
212 (20.6) |